Proliferatory defect of invariant population and accumulation of non-invariant CD1d-restricted natural killer T cells in the joints of RA patients

References

• Baxter AG, Kinder SJ, Hammond KJ, Scollay R, Godfrey DI. Association between alphabetaTCR+ CD4-CD8- T-cell deficiency and IDDM in NOD/Lt mice. Diabetes. 1997;46(4):572–82.
   PubMed Web of Science ®Google Scholar
• Godfrey DI, Kinder SJ, Silvera P, Baxter AG. Flow cytometric study of T cell development in NOD mice reveals a deficiency in alphabeta TCR+ CDR-CD8- thymocytes. J Autoimmun. 1997;10(3):279–85.
   PubMed Web of Science ®Google Scholar
• Takeda K, Hayakawa Y, Van Kaer L, Matsuda H, Yagita H, Okumura K. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Natl Acad Sci U S A. 2000;97(10):5498–503.
   PubMed Web of Science ®Google Scholar
• Gombert JM, Herbelin A, Tancrede-Bohin E, Dy M, Carnaud C, Bach JF. Early quantitative and functional deficiency of NK1+-like thymocytes in the NOD mouse. Eur J Immunol. 1996;26(12): 2989–98.
   PubMed Web of Science ®Google Scholar
• Matsuki N, Stanic AK, Embers ME, Van Kaer L, Morel L, Joyce S. Genetic dissection of V alpha 14J alpha 18 natural T cell number and function in autoimmune-prone mice. J Immunol. 2003; 170(11):5429–37.
   PubMed Web of Science ®Google Scholar
• Yang JQ, Wen X, Liu H, Folayan G, Dong X, Zhou M, et al. Examining the role of CD1d and natural killer T cells in the development of nephritis in a genetically susceptible lupus model. Arthritis Rheum. 2007;56(4):1219–33.
   PubMed Web of Science ®Google Scholar
• Araki M, Kondo T, Gumperz JE, Brenner MB, Miyake S, Yamamura T. Th2 bias of CD4 + NKT cells derived from multiple sclerosis in remission. Int Immunol. 2003;15(2):279–88.
   PubMed Web of Science ®Google Scholar
• van der Vliet HJ, von Blomberg BM, Nishi N, Reijm M, Voskuyl AE, van Bodegraven AA, et al. Circulating V(alpha24+) Vbeta11 + NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin Immunol. 2001;100(2):144–8.
   PubMed Web of Science ®Google Scholar
• Wilson SB, Kent SC, Patton KT, Orban T, Jackson RA, Exley M, et al. Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes. Nature. 1998;391(6663):177–81.
   PubMed Web of Science ®Google Scholar
• Oikawa Y, Shimada A, Yamada S, Motohashi Y, Nakagava Y, Irie J, et al. High frequency of valpha24(+) vbeta11(+) T-cells observed in type 1 diabetes. Diabetes Care. 2002;25(10):1818–23.
   PubMed Web of Science ®Google Scholar
• Lee PT, Putnam A, Benlagha K, Teyton L, Gottlieb PA, Bendelac A. Testing the NKT cell hypothesis of human IDDM pathogenesis. J Clin Invest. 2002;110(6):793–800.
   PubMed Web of Science ®Google Scholar
• Lantz O, Bendelac A. An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4 + and CD4-8- T cells in mice and humans. J Exp Med. 1994;180(3):1097–106.
   PubMed Web of Science ®Google Scholar
• Porcelli S, Yockey CE, Brenner MB, Balk SP. Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4- 8- alpha/beta T cells demonstrates preferential use of several V beta genes and an invariant TCR alpha chain. J Exp Med. 1993;178(1): 1–16.
   PubMed Web of Science ®Google Scholar
• Arase H, Arase N, Ogasawara K, Good RA, Onoe K. An NK1.1 + CD4 + 8- single-positive thymocyte subpopulation that expresses a highly skewed T-cell antigen receptor V beta family. Proc Natl Acad Sci U S A. 1992;89(14):6506–10.
   PubMed Web of Science ®Google Scholar
• Porcelli S, Gerdes D, Fertig AM, Balk SP. Human T cells expressing an invariant V alpha 24-J alpha Q TCR alpha are CD4- and heterogeneous with respect to TCR beta expression. Hum Immunol. 1996;48(1–2):63–7.
   PubMed Web of Science ®Google Scholar
• Kojo S, Adachi Y, Keino H, Taniguchi M, Sumida T. Dysfunction of T cell receptor AV24AJ18+, BV11 + double-negative regulatory natural killer T cells in autoimmune diseases. Arthritis Rheum. 2001;44(5):1127–38.
   PubMed Web of Science ®Google Scholar
• Linsen L, Thewissen M, Baeten K, Somers V, Geusens P, Raus J, Stinissen P. Peripheral blood but not synovial fluid natural killer T cells are biased towards a Th1-like phenotype in rheumatoid arthritis. Arthritis Res Ther. 2005;7(3):R493–502.
   Web of Science ®Google Scholar
• Maeda T, Keino H, Asahara H, Taniguchi M, Nishioka K, Sumida T. Decreased TCR AV24AJ18 + double-negative T cells in rheumatoid synovium. Rheumatology (Oxford). 1999;38(2):186–8.
   PubMed Web of Science ®Google Scholar
• Lin H, Nieda M, Nicol AJ. Differential proliferative response of NKT cell subpopulations to in vitro stimulation in presence of different cytokines. Eur J Immunol. 2004;34(10):2664–71.
   PubMed Web of Science ®Google Scholar
• Gadola SD, Dulphy N, Salio M, Cerundolo V. Valpha24-JalphaQ-independent, CD1d-restricted recognition of alpha-galactosylceramide by human CD4(+) and CD8alphabeta(+) T lymphocytes. J Immunol. 2002;168(11):5514–20.
   PubMed Web of Science ®Google Scholar
• Gumperz JE, Miyake S, Yamamura T, Brenner MB. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med. 2002;195(5):625–36.
   PubMed Web of Science ®Google Scholar
• Renukaradhya GJ, Khan MA, Vieira M, Du W, Gervay-Hague J, Brutkiewicz RR. Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma. Blood. 2008;111(12):5637–45.
   PubMed Web of Science ®Google Scholar
• Halder RC, Aguilera C, Maricic I, Kumar V. Type II NKT cell-mediated anergy induction in type I NKT cells prevents inflammatory liver disease. J Clin Invest. 2007;117(8):2302–12.
   PubMed Web of Science ®Google Scholar
• Thedrez A, de Lalla C, Allain S, Zaccagnino L, Sidobre S, Garavaglia C, et al. CD4 engagement by CD1d potentiates activation of CD4 + invariant NKT cells. Blood. 2007.
   PubMed Web of Science ®Google Scholar
• Lee PT, Benlagha K, Teyton L, Bendelac A. Distinct functional lineages of human V(alpha)24 natural killer T cells. J Exp Med. 2002;195(5):637–41.
   PubMed Web of Science ®Google Scholar
• Kim CH, Butcher EC, Johnston B. Distinct subsets of human Valpha24-invariant NKT cells: cytokine responses and chemokine receptor expression. Trends Immunol. 2002;23(11):516–9.
   PubMed Web of Science ®Google Scholar
• Stetson DB, Mohrs M, Reinhardt RL, Baron JL, Wang ZE, Gapin L, et al. Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised for rapid effector function. J Exp Med. 2003; 198(7):1069–76.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Chiba S, Nieda M, Azuma T, Ishihara S, Shibata Y, et al. Cutting edge: analysis of human V alpha 24 + CD8+ NK T cells activated by alpha-galactosylceramide-pulsed monocyte-derived dendritic cells. J Immunol. 2002;168(7):3140–4.
   PubMed Web of Science ®Google Scholar
• Mendiratta SK, Martin WD, Hong S, Boesteanu A, Joyce S, Van Kaer L. CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4. Immunity. 1997;6(4):469–77.
   PubMed Web of Science ®Google Scholar
• Exley M, Garcia J, Balk SP, Porcelli S. Requirements for CD1d recognition by human invariant Valpha24 + CD4-CD8- T cells. J Exp Med. 1997;186(1):109–20.
   PubMed Web of Science ®Google Scholar
• Arase H, Arase N, Nakagawa K, Good RA, Onoe K. NK1.1 + CD4+ CD8- thymocytes with specific lymphokine secretion. Eur J Immunol. 1993;23(1):307–10.
   PubMed Web of Science ®Google Scholar
• Yoshimoto T, Paul WE. CD4pos, NK1.1pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. J Exp Med. 1994;179(4):1285–95.
   PubMed Web of Science ®Google Scholar
• Cui J, Shin T, Kawano T, Sato H, Kondo E, Toura I, et al. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science. 1997;278(5343):1623–6.
   PubMed Web of Science ®Google Scholar
• Mattner J, Debord KL, Ismail N, Goff RD, Cantu C III, Zhou D, et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature. 2005;434(7032):525–9.
   PubMed Web of Science ®Google Scholar
• Beaudoin L, Laloux V, Novak J, Lucas B, Lehuen A. NKT cells inhibit the onset of diabetes by impairing the development of pathogenic T cells specific for pancreatic beta cells. Immunity. 2002;17(6):725–36.
   PubMed Web of Science ®Google Scholar
• Hong S, Wilson MT, Serizawa I, Wu L, Singh N, Naidenko OV, et al. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med. 2001;7(9):1052–6.
   PubMed Web of Science ®Google Scholar
• Sharif S, Arreaza GA, Zucker P, Mi QS, Sondhi J, Naidenko OV, et al. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat Med. 2001;7(9):1057–62.
   PubMed Web of Science ®Google Scholar
• Gumperz JE, Roy C, Makowska A, Lum D, Sugita M, Podrebarac T, et al. Murine CD1d-restricted T cell recognition of cellular lipids. Immunity. 2000;12(2):211–21.
   PubMed Web of Science ®Google Scholar
• Pridgeon C, Lennon GP, Pazmany L, Thompson RN, Christmas SE, Moots RJ. Natural killer cells in the synovial fluid of rheumatoid arthritis patients exhibit a CD56bright,CD94bright,CD158negative phenotype. Rheumatology (Oxford). 2003;42(7):870–8.
   PubMed Web of Science ®Google Scholar
• Chiba A, Oki S, Miyamoto K, Hashimoto H, Yamamura T, Miyake S. Suppression of collagen-induced arthritis by natural killer T cell activation with OCH, a sphingosine-truncated analog of alpha-galactosylceramide. Arthritis Rheum. 2004;50(1):305–13.
   PubMed Web of Science ®Google Scholar
• Oki S, Chiba A, Yamamura T, Miyake S. The clinical implication and molecular mechanism of preferential IL-4 production by modified glycolipid-stimulated NKT cells. J Clin Invest. 2004;113(11):1631–40.
   PubMed Web of Science ®Google Scholar
• Lee A, Farrand KJ, Dickgreber N, Hayman CM, Jürs S, Hermans IF, et al. Novel synthesis of alpha-galactosyl-ceramides and confirmation of their powerful NKT cell agonist activity. Carbohydr Res. 2006;341(17):2785–98.
   PubMed Web of Science ®Google Scholar
• Zhang L, Yuan S, Cheng G, Guo B. Type I IFN promotes IL-10 production from T cells to suppress Th17 cells and Th17-associated autoimmune inflammation. PLoS One. 2011;6(12):e28432.
   Web of Science ®Google Scholar
• Yang M, Deng J, Liu Y, Ko KH, Wang X, Jiao Z, et al. IL-10-producing regulatory B10 cells ameliorate collagen-induced arthritis via suppressing Th17 cell generation. Am J Pathol. 2012; 180(6):2375–85.
   PubMed Web of Science ®Google Scholar
• Liu B, Tonkonogy SL, Sartor RB. Antigen-presenting cell production of IL-10 inhibits T-helper 1 and 17 cell responses and suppresses colitis in mice. Gastroenterology. 2011;141(2):653–62.
   PubMed Web of Science ®Google Scholar
• Liu Y, Teige A, Mondoc E, Ibrahim S, Holmdahl R, Issazadeh- Navikas S. Endogenous collagen peptide activation of CD1d-restricted NKT cells ameliorates tissue-specific inflammation in mice. J Clin Invest. 2011;121(1):249–64.
   PubMed Web of Science ®Google Scholar
• Jung S, Park YK, Shin JH, Lee H, Kim SY, Lee GR, Park SH. The requirement of natural killer T-cells in tolerogenic APCs-mediated suppression of collagen-induced arthritis. Exp Mol Med. 2010;42(8):547–54.
   PubMed Web of Science ®Google Scholar
• Teige A, Bockermann R, Hasan M, Olofsson KE, Liu Y, Issazadeh-Navikas S. CD1d-dependent NKT cells play a protective role in acute and chronic arthritis models by ameliorating antigen-specific Th1 responses. J Immunol. 2010;185(1):345–56.
   PubMed Web of Science ®Google Scholar
• Horikoshi M, Goto D, Segawa S, Yoshiga Y, Iwanami K, Inoue A, et al. Activation of Invariant NKT cells with glycolipid ligand α-galactosylceramide ameliorates glucose-6-phosphate isomerase peptide-induced arthritis. PLoS One. 2012;7(12):e51215.
   Web of Science ®Google Scholar
• Hu M, Bassett JH, Danks L, Howell PG, Xu K, Spanoudakis E, et al. Activated invariant NKT cells regulate osteoclast development and function. J Immunol. 2011;186(5):2910–7.
   PubMed Web of Science ®Google Scholar
• Park Y, Kim HS, Ahn JY, Yun D, Cho ML, Hong S, et al. IL-12p35 promotes antibody-induced joint inflammation by activating NKT cells and suppressing TGF-beta. J Immunol. 2010;185(3):1476–84.
   PubMed Web of Science ®Google Scholar